Across TCGA pan-cancer cohorts, TM2D3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TM2D3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TM2D3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TM2D3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where TM2D3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.575	1.000	.001	27	view →
GBM	DFS	Median	All	0.235	0.554	.004	11	view →
PDAC	OS	Median	II,III,IV	0.786	1.000	.008	9	view →
LUAD	OS	Tertile	II,III,IV	0.514	0.819	.011	7	view →
LSCC	OS	Median	II,III,IV	1.000	0.833	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TM2D3 tumor-vs-normal RNA expression · all TM2D3 data types